miRNA extracted from extracellular vesicles is a robust biomarker of amyotrophic lateral sclerosis

For Public Health

Key points

Describes a methodology of using miRNA extracted from extracellular blood vesicles as viable biomarkers to identify ALS in a population sample. Utilizes National ALS Biorepository biospecimen and identifies miRNA signature different from controls.
Screenshot of the first two pages of the paper

Affiliates

Sandra A. Banack [1], Rachael A. Dunlop [1], Elijah Stommel [2] ,Paul Mehta [3], Paul A. Cox [1]

  1. Brain Chemistry Labs, Jackson, WY, USA
  2. Department of Neurology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA
  3. Centers for Disease Control and Prevention/Agency for Toxic Substances and Disease Registry, National ALS Registry (CDC/ATSDR), Atlanta, GA, USA

Journal

Journal of the Neurological Sciences

Summary

This research paper describes a methodology of using miRNA extracted from extracellular blood vesicles as viable biomarkers to identify ALS in a population sample. Blood plasma was obtained from the National ALS Biorepository and compared with non-ALS controls. Eight miRNA biomarkers were investigated and five out of those eight were found to significantly discriminate ALS samples from the controls. The paper proposes further research and development into these eight miRNA pre-symptomatic identifying biomarkers.

Link to Paper

Read the paper here!

Print
Content Source
Agency for Toxic Substances and Disease Registry
About This Page
Published: November 12, 2024
Updated: November 11, 2024

This page was last updated on this date. Updates may include minor edits, image changes, or other modifications to page content.

Reviewed: September 10, 2026

The information on this page was last reviewed by subject matter experts to ensure accuracy.